Content about Arthritis

September 4, 2013

Expanding the role of pharmacists in Canada is one solution that will reduce the burden of chronic illness on patients, and save the system an estimated C$1.4 billion to C$1.9 billion dollars over three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.

TORONTO — Expanding the role of pharmacists in Canada is one solution that will reduce the burden of chronic illness on patients, and save the system an estimated C$1.4 billion to C$1.9 billion dollars over three years, according to a new report released by Arthritis Consumer Experts, the Arthritis Research Centre of Canada and Shoppers Drug Mart.

August 28, 2013

The results of a large survey of patients with rheumatoid arthritis have been published, the company that conducted the survey said Wednesday.

PHILADELPHIA — The results of a large survey of patients with rheumatoid arthritis have been published, the company that conducted the survey said Wednesday.

August 6, 2013

Hospira posted sales of $1 billion during second quarter 2013, a 0.7% decrease compared with second quarter 2012, the generic drug maker said.

LAKE FOREST, Ill. — Hospira posted sales of $1 billion during second quarter 2013, a 0.7% decrease compared with second quarter 2012, the generic drug maker said.

Hospira, which specializes in making generic injectables, also posted $318.7 million gross profit, a 12.4% increase over second quarter 2012's $283.5 million.

July 2, 2013

Arthritis is one of the most common chronic illnesses in children, but it often goes unnoticed and undiagnosed, according to two arthritis-focused organizations seeking to spread awareness about the disease.

ATLANTA — Arthritis is one of the most common chronic illnesses in children, but it often goes unnoticed and undiagnosed, according to two arthritis-focused organizations seeking to spread awareness about the disease.

The Arthritis Foundation has designated July as Juvenile Arthritis Awareness Month, highlighting the approximately 300,000 children affected by the condition. Children suffering from achy joints are often diagnosed as having "growing pains," but pain, stiffness and swelling in and around the joints may be signs of more serious rheumatic disease.

May 10, 2013

The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.

EAST HANOVER, N.J. — The Food and Drug Administration has approved a biotech drug made by Novartis for treating a form of arthritis that affects children, the Swiss drug maker said Friday.

April 30, 2013

The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a drug made by Genentech for a rare form of arthritis in children, the company said Tuesday.

Genentech, a subsidiary of Swiss drug maker Roche, announced the approval of Actemra (tocilizumab) for polyarticular juvenile idiopathic arthritis in children ages 2 years and older, either alone or combined with the generic drug methotrexate.

April 8, 2013

An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

NEW YORK — An experimental drug developed by AstraZeneca for rheumatoid arthritis produced mixed results in measurements of patients' conditions, according to results of a late-stage clinical trial.

AstraZeneca announced initial results of the phase-3 "OSKIRA-1" trial of fostamatinib, which it calls the first oral spleen tyrosine kinase inhibitor in development for RA.

April 2, 2013

Specialty drugs are expected to account for 50% of all drug costs by 2018, according to two new studies.

SAN DIEGO — Specialty drugs are expected to account for 50% of all drug costs by 2018, according to two new studies.

By contrast, specialty drugs accounted for 20% of all drug costs in 2009, but increased to 28.7% by 2012. Pharmacy benefit manager Prime Therapeutics and Blue Cross and Blue Shield of Minnesota conducted the studies, and Prime is presenting them Tuesday at the Academy of Managed Care Pharmacy's 25th annual meeting and expo in San Diego.

March 25, 2013

More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

WASHINGTON — More than 400 drugs are under development for the 10 most common chronic health conditions affecting elderly people, according to a new report by a drug industry trade group.

December 18, 2012

A new product makes gripping such things as eating utensils, pens and toothbrushes easier for people with arthritis.

WAYNE, N.J. — A new product makes gripping such things as eating utensils, pens and toothbrushes easier for people with arthritis.

Maddak announced the availability of the Universal Built-Up Handle, designed as a "do-it-yourself" product to enlarge the gripping surfaces of common household items.

December 6, 2012

Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat active psoriatic arthritis, the company said Thursday.

HORSHAM, Pa. — Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat active psoriatic arthritis, the company said Thursday.

J&J subsidiary Janssen Biotech submitted an application to the FDA for Stelara (ustekinumab) for adult patients with the disease, which affects more than 2 million people in the United States, according to the National Psoriasis Foundation. Another subsidiary is seeking approval for Stelara for the same usage in Europe.

November 13, 2012

Patients with a form of arthritis that affects young people taking a drug made by Abbott experienced improvements in their condition after a year of treatment, according to late-stage clinical trial results.

ABBOTT PARK, Ill. — Patients with a form of arthritis that affects young adults taking a drug made by Abbott experienced improvements in their condition after a year of treatment, according to late-stage clinical trial results.

Abbott announced Monday the first long-term patient-reported health outcomes data for the phase-3 "ABILITY-1" trial of Humira (adalimumab) in patients with nonradiographic axial spondyloarthritis, or nr-axSpA. Results of the trial were presented at the American College of Rheumatology's annual scientific meeting in Washington.

November 6, 2012

The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for rheumatoid arthritis ahead of the day the agency was scheduled to decide whether or not to approve it, the agency said Tuesday.

October 17, 2012

Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy.

LONDON — Vitamin D supplementation could be considered an immunomodulatory agent for systemic lupus erythematosus, an autoimmune disease characterized not only by skin, joint, neurological and renal symptoms, but also by inflammation of tissue linings in the body, according to a new clinical study published Tuesday in BioMedCentral's open access journal Arthritis Research and Therapy

An immunomodulatory agent has an effect on the immune system. 

October 12, 2012

The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

SOUTH SAN FRANCISCO, Calif. — The Food and Drug Administration has approved a new use for a drug made by Roche division Genentech.

The drug maker said Friday that the FDA had approved Actemra (tocilizumab) for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to one or more disease-modifying antirheumatic drugs. The drug was already approved for systemic juvenile idiopathic arthritis.

October 9, 2012

The Food and Drug Administration has approved a drug made by Acton Pharmaceuticals for asthma, the company said.

SUPPLIER NEWS — The Food and Drug Administration has approved a drug made by Acton Pharmaceuticals for asthma, the company said. The drug maker announced the approval of Aerospan (flunisolide HFA) inhalation aerosol as a maintenance treatment for asthma in patients ages 6 years and older. The drug maker plans to launch the drug in early 2013.

September 28, 2012

The Food and Drug Administration has approved a drug made by Abbott for treating ulcerative colitis.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Abbott for treating ulcerative colitis.

The agency announced Friday the approval of Humira (adalimumab) for moderate to severe UC. The drug was already approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, plaque psoriasis and juvenile idiopathic arthritis.

UC is a chronic disease that affects about 620,000 Americans, according to the National Institutes of Health.

September 19, 2012

A subsidiary of Johnson & Johnson is hoping to gain Food and Drug Administration approval for a new formulation of one of its drugs.

HORSHAM, Pa. — A subsidiary of Johnson & Johnson is hoping to gain Food and Drug Administration approval for a new formulation of one of its drugs.

Janssen Biotech announced that it had filed an application with the FDA seeking approval for an intravenous formulation of Simponi (golimumab) in adults with moderately to severely active rheumatoid arthritis, which affects an estimated 1.5 million Americans.

August 29, 2012

A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

WASHINGTON — A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

According to published reports, the panel voted 15-2 that the benefits of Humira outweighed the risks in treating ulcerative colitis. However, the panel asked Abbott to conduct more studies upon Humira's approval.

August 23, 2012

A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

SPRING HOUSE, Pa. — A division of Johnson & Johnson has started a late-stage clinical trial program for a drug for rheumatoid arthritis under a partnership with British drug maker GlaxoSmithKline.

July 27, 2012

Horizon Pharma announced it has received regulatory approval from the Food and Drug Administration for one of its drugs.

DEERFIELD, Ill. — Horizon Pharma announced it has received regulatory approval from the Food and Drug Administration for one of its drugs.

The drug maker said Rayos (prednisone) delayed-release tablets — in the 1-mg, 2-mg and 5-mg stregnths — were approved for the treatment of rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, ankylosing spondylitis, asthma and chronic obstructive pulmonary disease.

July 17, 2012

A subsidiary of Johnson & Johnson is hoping to win an additional approval for one of its drugs.

HORSHAM, Pa. — A subsidiary of Johnson & Johnson is hoping to win an additional approval for one of its drugs.

Janssen Biotech and Janssen Biologics B.V. announced the submission of a supplemental regulatory application to the Food and Drug Administration for Simponi (golimumab) for treatment of moderately to severely active ulcerative colitis, an inflammatory bowel disease that affects about 700,000 people in the United States. The drug already is approved for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

December 20, 2011

Pfizer is seeking approval from the Food and Drug Administration for its investigational treatment of moderately to severely active rheumatoid arthritis.

NEW YORK — Pfizer is seeking approval from the Food and Drug Administration for its investigational treatment of moderately to severely active rheumatoid arthritis.

The company said the FDA accepted a new drug application for tofacitinib for review. The agency also has provided an anticipated Prescription Drug User Fee Act action date of August 2012. Tofacitinib, which is a novel, oral JAK inhibitor, currently is under review by the European Medicines Agency.

November 17, 2011

The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

MOUNTAIN VIEW, Calif. — The increase in the number of people with rheumatoid arthritis, and the challenges posed to drug makers by generics, is encouraging the development of new drugs for the disease, according to a new report by Frost & Sullivan.

November 7, 2011

The first study to report the effects vitamin D has on the immune system of people with lupus was unveiled Saturday at the American College of Rheumatology Annual Scientific Meeting in Chicago.

CHICAGO — The first study to report the effects vitamin D has on the immune system of people with lupus was unveiled Saturday at the American College of Rheumatology Annual Scientific Meeting here.

The small sample study determined that vitamin D supplementation helped improve cell level counts associated with the disease.